ArticleF1000Research2020

ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.

Andrew Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.